BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines XGEVA (denosumab, RANKL Inhibitor by Year
XGEVA (denosumab, RANKL Inhibitor — Amgen In-Licensed) ($M) ($M)
BeOne Medicines XGEVA (denosumab, RANKL Inhibitor: $306M in FY2025, up 36.4% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Segment Disaggregation Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | XGEVA (denosumab, RANKL Inhibitor — Amgen In-Licensed) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 306 | +36.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 224 | +141.8% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 92.8 | +46.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 63.4 | +37.8% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 46 | +441.2% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 8.50 | – | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). BeOne Medicines XGEVA (denosumab, RANKL Inhibitor ($M), annual FY2018–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-xgeva
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.